study will be to determine whether, in a different tumour microenvironment, CAFs also influence metastatic seeding and tumour growth dynamics.
Lenos et al. have elegantly described the growth kinetics and dynamics of colorectal tumours, and identified OPN as a secreted factor by which CAFs can dictate tumour cell fate. These data illuminate a previously underappreciated concept that stromal cues can influence tumour cell hierarchy and subsequently have profound effects on the tumour mass as a whole. Importantly, this newly emphasised role for molecular determinants of stemness in established tumours shifts the focus from targeting tumour cell populations that 
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The authors declare no competing interests. ), which generates highly reactive free radicals that cause peroxidation of unsaturated fatty acids in membrane lipids leading to ferroptosis, a regulated form of cell death 3, 4 . However, the function and regulation of ferroptosis in tumorigenesis remains unknown.
In this issue of Nature Cell Biology, Zhang et al. 5 demonstrate that ferroptosis is metabolically regulated by BRCAassociated protein 1 (BAP1) through the cystine transporter SLC7A11, and thus at least partly accounts for the tumoursuppressing function of BAP1. A known tumour suppressor, BAP1 functions as a deubiquinitase (DUB) and removes ubiquitin (Ub) from histone 2A (H2A), thereby regulating gene expression 6, 7 . Mutations to BAP1 lead to various types of cancers such as renal cell carcinoma and mesothelioma 7 . The authors now show that BAP1 mutations enable tumour cells to evade ferroptosis and continue to form malignant lesions.
Zhang et al. started by identifying genes that are transcriptionally regulated by BAP1-dependent H2A-Ub occupancies, using an elegant combination of transcriptomics, epigenomic analyses and cancer genomics. In the UMRC6 cell line that has low levels of BAP1, they expressed an active or inactive, mutated form of BAP1, followed by chromatin immunoprecipitation sequencing (ChIPseq) to compare the genome-wide occupancies of H2A-Ub. This revealed that BAP1 decreased H2A-Ub occupancies for more than 5,000 genes. In parallel, they used RNA-sequencing to identify genes whose expression was changed in response to BAP1 activity. Combining the two data sets led to a manageable set of genes that fitted the expected pattern of lower expression when BAP1 deubiquitinated the associated H2A. To pinpoint the candidate genes associated with cancer, the authors analysed BAP1 levels, gene expression profiles and patient survival in a Cancer Genome Atlas (TCGA) kidney clear cell carcinoma (KIRC) data set compared with that of normal cells, and identified SLC7A11, which was prominently downregulated in response to BAP1 expression (Fig. 1) . SLC7A11 was also among the top hits identified in the RNA-sequencing and ChIP-seq analysis of UMRC6 cells. This finding is in line with a recent study reporting that p53 activates ferroptosis by suppressing the expression of SLC7A11 (ref. 8 ), implicating SLC7A11 as a promising candidate gene responsible for tumour suppression by BAP1. The authors further showed that BAP1 expression was inversely correlated with that of SLC7A11 in KIRC and other types of cancer. In addition, re-expression of active BAP1, but not of its inactive, mutant form, in BAP1-deficient cells decreased H2A-Ub occupancy of the SLC7A11 promoter and gene region, and reduced SLC7A11 expression. Together, these data indicate that BAP1 acts as a tumour suppressor by decreasing SLC7A11 expression to enhance cell death.
SLC7A11 is a cystine-glutamate exchanger that takes up cystine into the cell 9 . Cystine is critical for glutathione (GSH) synthesis, a major component of the cell's antioxidant defences. Crucially, downregulating expression of SLC7A11, or inhibiting its activity with erastin, leads to cell death by ferroptosis 3, 4 . Ferroptosis occurs when free iron induces lipid peroxidation, and therefore inhibition of glutathione peroxidase 4 (GPX4) (which degrades the lipid hydroperoxides generated during lipid peroxidation) greatly enhances ferroptosis 3, 4, 10 . Lipid peroxidation also generates a range of reactive aldehyde by-products that cause damage by modifying amines on proteins and DNA, and GSH inactivates these damaging species when catalysed by glutathione-S-transferases (GSTs) 11 . Ferroptosis can also be prevented by lipophilic antioxidants, such as vitamin E, and by iron chelators 3, 4 . The link between SLC7A11 and ferroptosis led Zhang et al. to propose that BAP1 acts as a tumour suppressor by downregulating the expression of SLC7A11 in transformed cells. Indeed, BAP1 overexpression in UMRC6 cells led to suppressed cystine uptake, decreased GSH levels and increased ferroptosis induced by erastin treatment. These effects were abrogated by restored SLC7A11 expression. In addition, SLC7A11 re-expression in BAP1-expressing UMRC6 cells partially restored xenograft tumour development. Mutations that inactivate BAP1 enabled cancer cells to maintain their supply of GSH, fend off death by ferroptosis and form tumours. Supporting the idea that ferroptosis is a normal mode of cell death in preventing cancer, the authors also observed condensed mitochondria by electron microscopy in tumours caused by BAP1 mutations, suggesting that these cells die by ferroptosis 12 .
These intriguing findings have a number of implications. One is that we can add ferroptosis to the range of methods cells use to prevent cancer arising. It will be interesting to see how widespread ferroptosis is compared to apoptosis in preventing cancer initiation. This further raises the question of how ferroptosis is regulated. Is suppression of cystine supply to the cell all that is required to set off cell death by ferroptosis? If so, it implies that many cells are at risk of undergoing ferroptosis. However, it is more likely that induction of ferroptosis requires several steps, potentially including enhanced iron uptake or release from internal stores. It is also conceivable that ferroptosis is constrained by multiple mechanisms, similar to apoptosis 13 . This work also suggests new therapeutic approaches. An obvious strategy is to inhibit cystine-uptake to starve transformed cells of cysteine, as demonstrated in vitro with the SLC7A11-inhibitor erastin in the study. In addition, inhibition of GPX4, for example with RSL3 (ref. 10 ), is also likely to induce ferroptosis in cancer cells. Other approaches worth considering as combination therapies include elevating oxidative stress by enhancing free radical generation, or depleting antioxidant defences, for example by sequestering GSH.
Zhang et al. have used an elegant heuristic approach to explore the function of tumour suppresser BAP1, and in the process have uncovered a role for ferroptosis in suppressing cancer that is enhanced by attenuating cystine uptake. These findings expand our knowledge on cellular mechanisms that prevent cancer and provide further insights into the process of free radical production and the role of oxidative stress in the cell. Finally, this work suggests that ferroptosis not only arises as part of the pathology of tissue injury, but that in some circumstances it may be part of a physiological process 3, 4 . 
